Novel FOXM-1 inhibitors for diagnosis and treatment of cancer

Description

Researchers at the University of Alberta are utilizing their new insights into the mechanism of action of FOXM-1 inhibitors to design first in class oncology drugs targeting FOXM-1 protein. In addition, novel radiolabeled probes can detect FOXM-1 expressing tumor tissue for companion diagnostic purposes.

FOXM-1 is a transcription factor involved in cancer cell proliferation. Its expression […]

By |August 2nd, 2018|Licensing Opportunities|0 Comments

Novel SERS-Based Biosensing platform for prostate cancer

Description

Researchers at the University of Alberta have developed biogenic silver nanoparticles which can be used as plasmonic labels for enhanced spectroscopy applications. The nanoparticles can be modified with Raman active molecules either in situ or post production. The detection platform for biosensing targets the AR-V7 biomarker for metastatic castration resistant prostate cancer. The platform predicts […]

By |August 2nd, 2018|Licensing Opportunities|0 Comments